FDA grants accelerated access for Kymriah (Cell and Gene Therapy Catapult – Regulatory Round-up- May 2022)
Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings.
See all of Catapult’s Regulatory Round-up for May 2022 here.
Published on the 6th of June 2022.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (3 août 2022). FDA grants accelerated access for Kymriah (Cell and Gene Therapy Catapult – Regulatory Round-up- May 2022). ELSIBI. Consulté le 7 octobre 2026 à l’adresse https://doi.org/10.58079/o61m
